Current research focuses on improving the therapeutic impact of sabatolimab and other new anti-TIM-3 mAbs, through improved combination strategies or biomarker-based patient selection, to better address the challenges of immune resistance in NSCLC (Table 3). This evidence concerns the gene HAVCR2 and non-small cell lung carcinoma.